Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)
Immunome reported positive Phase 3 results for varegacestat in desmoid tumors, showing an 84% reduction in risk of progression or death versus placebo. The company also announced a proposed $400 million stock offering, raising concerns about dilution. Most side effects were mild, but 55.6% of premenopausal women experienced ovarian toxicity. Shares moved sharply on the news.